INM (InMed Pharmaceuticals) Cyclically Adjusted Book per Share: $686.21 (As of Mar. 2026)


INM InMed Pharmaceuticals Inc INM
29 GF Score
Price $1.65
GF Value $0.93
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is InMed Pharmaceuticals Cyclically Adjusted Book per Share?

InMed Pharmaceuticals INM -0.61% 29 Cyclically Adjusted Book per Share is $686.21 as of Mar. 2026. GuruFocus rates INM with a GF Score™ of 29/100 and a GF Value™ of $0.93 (Significantly Overvalued). The stock has 4 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

InMed Pharmaceuticals's adjusted book value per share for the three months ended in Mar. 2026 was $2.080. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $686.21 for the trailing ten years ended in Mar. 2026.

During the past 12 months, InMed Pharmaceuticals's average Cyclically Adjusted Book Growth Rate was -1.60% per year. During the past 3 years, the average Cyclically Adjusted Book Growth Rate was -0.30% per year. During the past 5 years, the average Cyclically Adjusted Book Growth Rate was 6.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of InMed Pharmaceuticals was 169.10% per year. The lowest was -17.40% per year. And the median was 20.20% per year.

As of today (2026-07-11), InMed Pharmaceuticals's current stock price is $1.65. InMed Pharmaceuticals's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2026 was $686.21. InMed Pharmaceuticals's Cyclically Adjusted PB Ratio of today is 0.00.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of InMed Pharmaceuticals was 1.02. The lowest was 0.01. And the median was 0.03.


InMed Pharmaceuticals  (NAS:INM) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

InMed Pharmaceuticals's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=1.65/686.21
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of InMed Pharmaceuticals was 1.02. The lowest was 0.01. And the median was 0.03.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


InMed Pharmaceuticals Cyclically Adjusted Book per Share Related Terms


InMed Pharmaceuticals Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for InMed Pharmaceuticals's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

InMed Pharmaceuticals Cyclically Adjusted Book per Share Chart

InMed Pharmaceuticals Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 604.02 696.46 732.29 736.78 690.97

InMed Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 697.27 690.97 685.71 680.36 686.21

INM vs SNOA, CVSI, PRFX: Cyclically Adjusted Book per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, InMed Pharmaceuticals's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


InMed Pharmaceuticals Cyclically Adjusted PB Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, InMed Pharmaceuticals's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where InMed Pharmaceuticals's Cyclically Adjusted PB Ratio falls into.


INM
29GF Score
InMed Pharmaceuticals Inc INM
Cyclically Adjusted Book per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

InMed Pharmaceuticals Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, InMed Pharmaceuticals's adjusted Book Value per Share data for the three months ended in Mar. 2026 was:

Adj_Book= Book Value per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=2.08/132.2623*132.2623
=2.080

Current CPI (Mar. 2026) = 132.2623.

InMed Pharmaceuticals Quarterly Data

Book Value per Share CPI Adj_Book
201606 205.000 102.002 265.817
201609 237.500 101.765 308.676
201612 251.167 101.449 327.456
201703 441.143 102.634 568.493
201706 765.625 103.029 982.865
201709 745.250 103.345 953.784
201712 1,429.750 103.345 1,829.818
201803 1,264.556 105.004 1,592.826
201806 2,062.500 105.557 2,584.300
201809 1,990.600 105.636 2,492.345
201812 1,768.600 105.399 2,219.367
201903 1,623.900 106.979 2,007.687
201906 1,388.300 107.690 1,705.072
201909 1,132.400 107.611 1,391.804
201912 924.800 107.769 1,134.982
202003 679.600 107.927 832.833
202006 587.800 108.401 717.184
202009 449.400 108.164 549.522
202012 542.214 108.559 660.601
202103 650.875 110.298 780.490
202106 461.063 111.720 545.841
202109 724.857 112.905 849.133
202112 505.964 113.774 588.183
202203 375.414 117.646 422.057
202206 275.121 120.806 301.212
202209 244.622 120.648 268.171
202212 181.456 120.964 198.405
202303 74.627 122.702 80.441
202306 72.831 124.203 77.557
202309 57.699 125.230 60.939
202312 45.131 125.072 47.725
202403 35.032 126.258 36.698
202406 20.641 127.522 21.408
202409 12.586 127.285 13.078
202412 8.539 127.364 8.867
202503 5.818 129.181 5.957
202506 6.710 129.892 6.832
202509 4.451 130.287 4.518
202512 3.419 130.366 3.469
202603 2.080 132.262 2.080

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of $686.21 mean?
InMed Pharmaceuticals (INM) has a Cyclically Adjusted Book per Share of $686.21 as of Mar. 2026. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on InMed Pharmaceuticals and its competitors.
Is InMed Pharmaceuticals' Cyclically Adjusted Book per Share too high?
InMed Pharmaceuticals' current Cyclically Adjusted Book per Share is $686.21. Overall, InMed Pharmaceuticals has a GF Score™ of 29/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does InMed Pharmaceuticals' Cyclically Adjusted Book per Share compare to SNOA and CVSI?
InMed Pharmaceuticals' Cyclically Adjusted Book per Share of $686.21 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Book per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on InMed Pharmaceuticals and its competitors. InMed Pharmaceuticals's current Cyclically Adjusted Book per Share is $686.21. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is InMed Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, InMed Pharmaceuticals (INM) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.93, compared to a current price of $1.65 — trading 77.4% above its estimated fair value. The current Cyclically Adjusted Book per Share is $686.21. InMed Pharmaceuticals' overall GF Score™ is 29/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For InMed Pharmaceuticals (INM), the current Cyclically Adjusted Book per Share is $686.21 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is InMed Pharmaceuticals (INM) Overvalued in 2026?

Based on GuruFocus' analysis, InMed Pharmaceuticals stock appears to be overvalued. The current stock price of $1.65 is trading 77.4% above its estimated GF Value™ of $0.93. GuruFocus considers InMed Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for INM:

  • Cyclically Adjusted Book per Share: $686.21
  • GF Value™: $0.93 vs. price of $1.65 (77.4% above fair value)
  • GF Score™: 29/100 with 4 warning signs

No single metric tells the full story. See the INM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


InMed Pharmaceuticals Business Description

Other Exchanges MWG:Germany
Address 885 West Georgia Street, Suite 1445, Vancouver, BC, CAN, V6C 3E8
InMed Pharmaceuticals Inc is a pharmaceutical company developing a pipeline of disease-modifying small molecule drug candidates targeting CB1 and CB2 receptors. The company's pipeline consists of three separate programs in the treatment of Alzheimer's, ocular and dermatological indications.
29GF Score

Get the complete analysis for INM

Cyclically Adjusted Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.65
Price
$0.93
GF Value